| If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| | | ![]() DG DISPATCH - AAN: Pergolide improves restless legs symptoms By Richard Robinson Special to DG News
SAN DIEGO, CA -- May 2, 2000 -- Pergolide decreases limb movements and improves sleep in restless legs syndrome (RLS), according to a study presented Monday (May 1) at the 52nd Annual Meeting of the American Academy of Neurology, in San Diego, CA. Pergolide, a long-acting D1 and D2 dopamine receptor agonist, has been shown to be effective for RLS in short-term, double-blind trials. To test its efficacy in the long-term, Karen Stiasny, MD, a neurologist at Philipps University of Marburg, in Germany, and colleagues followed patients from their double-blind trial for more than a year on open-label pergolide. Twenty-two out of 28 eligible patients participatedin the trial. After a mean follow-up of 426 days, patients showed persistent improvement of better than 66 percent on the periodic limb movement index during both sleep and wakefulness compared to the pre-treatment baseline. They also showed significant improvements in total sleep time, sleep efficiency, and physician-rated clinical global impression. Patients rated their RLS symptoms to be improved compared to baseline, falling from 4.8 to 1.7 on a 10-point severity scale (p=0.0001), and reported continued satisfaction with their sleep quality, rising from 2.4 to 5.7 on a seven-point satisfaction scale (p=0.0001). Dopaminergic side effects were controlled with domperidone in those patients who required it. "There was a persistent, significant effect of low-dose pergolide on all primary symptoms of RLS," Dr. Stiasny concluded. RLS is a neurologic movement disorder marked by dysesthesias and motor restlessness in both sleep and wakefulness. The study, titled, "Long-term effect of pergolide in the treatment of restless legs syndrome," was supported by Lilly Deutschland.
|